- Home
- AEON vs CNSP Comparison
AEON vs CNSP Comparison
Compare AEON & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEON | CNSP |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 8.5M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AEON | CNSP |
|---|---|---|
| Price | $0.26 | $5.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.20 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 10.0M | 8.1K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $1.90 |
| 52 Week High | $1.45 | $10.59 |
Technical Indicators
Market Signals| Indicator | AEON | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 51.10 |
| Support Level | $0.26 | $5.44 |
| Resistance Level | $0.33 | $5.94 |
| Average True Range (ATR) | 0.04 | 0.22 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 34.34 | 45.61 |
Price Performance
Historical ComparisonAbout AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.